Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in Clin Ther

Retrieve available abstracts of 10 articles:
HTML format
Text format



Single Articles


    May 2018
  1. VISARIA J, Thomas N, Gu T, Singer J, et al
    Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice.
    Clin Ther. 2018 May 23. pii: S0149-2918(18)30186.
    PubMed     Text format     Abstract available


    March 2018
  2. KITA M, Fox RJ, Gold R, Giovannoni G, et al
    Corrigendum to 'Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (
    Clin Ther. 2018 Mar 7. pii: S0149-2918(18)30055.
    PubMed     Text format    


    December 2017
  3. MOTL RW, Sandroff BM
    Exercise as a Countermeasure to Declining Central Nervous System Function in Multiple Sclerosis.
    Clin Ther. 2017 Dec 26. pii: S0149-2918(17)31106.
    PubMed     Text format     Abstract available


    July 2017
  4. FERNANDEZ O, Giovannoni G, Fox RJ, Gold R, et al
    Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Clin Ther. 2017 Jul 24. pii: S0149-2918(17)30765.
    PubMed     Text format     Abstract available


    February 2017
  5. SOINI E, Joutseno J, Sumelahti ML
    Cost-Utility of First-Line Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Clin Ther. 2017 Feb 13. pii: S0149-2918(17)30074.
    PubMed     Text format     Abstract available


  6. VAN AMERONGEN G, Kanhai K, Baakman AC, Heuberger J, et al
    Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Delta9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis.
    Clin Ther. 2017 Feb 9. pii: S0149-2918(17)30054.
    PubMed     Text format     Abstract available


    February 2016
  7. N'GBO N'GBO IKAZABO R, Mostosi C, Quivron B, Delberghe X, et al
    Immune-Reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    Clin Ther. 2016 Feb 4. pii: S0149-2918(16)00023.
    PubMed     Text format     Abstract available


    November 2015
  8. APPLEBEE A, Goodman AD, Mayadev AS, Bethoux F, et al
    Effects of Dalfampridine Extended-Release Tablets on 6-Minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial.
    Clin Ther. 2015 Nov 9. pii: S0149-2918(15)01175.
    PubMed     Text format     Abstract available


    October 2015
  9. GIOVANNONI G, Gold R, Fox RJ, Kappos L, et al
    Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies.
    Clin Ther. 2015 Oct 30. pii: S0149-2918(15)01136.
    PubMed     Text format     Abstract available


    September 2015
  10. MILLER AE
    Teriflunomide: A Once-Daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis.
    Clin Ther. 2015 Sep 10. pii: S0149-2918(15)01009.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: